Choose a language and wait for the translated text.
The drug, arcotatug tavatecan, or TAK-921, met both those main goals of the trial in patients with advanced gastric or gastroesophageal junction cancer who had received at least two prior therapies.
Takeda to seek Japan approval for gastric cancer drug next year | PharmaVoice
